The Servier deal removes the muscular dystrophy pipeline risk and provides a massive cash infusion, but the company is now a single-asset cardiovascular biotech with no approved products. The key catalyst is the Phase 3 start for EDG-7500 in HCM in Q4 2026. Monitor for milestone payments from Servier (up to $1.1B) and any early efficacy/safety signals from the EDG-7500 Phase 3 program.
Price Chart
Executive Summary
Edgewise Therapeutics reported Q2 2026 net loss of $0.53/share, a 12.2% miss vs consensus of $-0.47, with no revenue. The quarter was dominated by the July 2026 completion of the sevasemten sale to Servier for $1.55B upfront (up to $2.65B total), transforming the balance sheet to a pro-forma $2.01B cash position and pivoting the company to a pure-play cardiovascular focus. Positive Phase 2 CIRRUS-HCM data for EDG-7500 supports a planned Phase 3 start in Q4 2026, but the company remains pre-revenue with widening operating losses as it funds the new pipeline.
Key Financial Metrics
Key Facts
- Net loss per share was $-0.53 for Q2 2026, compared to $-0.34 in Q2 2025, a 55.9% YoY increase in net loss.
- EPS of $-0.53 missed consensus of $-0.47 by 12.2%.
- Completed sale of sevasemten and muscular dystrophy business to Servier for $1.55B upfront cash (up to $2.65B total) in July 2026.
- Pro-forma cash balance post-sale is approximately $2.01B before taxes and transaction costs, up from $460.7M at quarter-end.
- Positive 12-week Phase 2 CIRRUS-HCM data for EDG-7500 announced; Phase 3 initiation expected in Q4 2026.
- R&D expenses rose 41.7% YoY to $47.5M, driven by EDG-7500, EDG-15400, and MESA extension study activity.
- Company has no revenue and is transitioning to a cardiovascular-focused biopharmaceutical company.
Financial Impact
Q2 net loss of $57.3M widened 58.7% YoY from $36.1M; pro-forma cash of ~$2.01B post-Servier deal provides >8 years of runway at current burn rate.
Risk Factors
- Single-asset dependency on EDG-7500 for HCM, with no approved products or revenue.
- Phase 3 clinical risk for EDG-7500; positive Phase 2 data may not replicate.
- Operating losses are widening as R&D spend increases for the cardiovascular pipeline.
- No guarantee of receiving the $1.1B in milestone payments from Servier.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-091671 |
| Document: tm2621653d1_8k.htm | 0001104659-26-091671 |
| Document: 0001104659-26-091671-index-headers.html | 0001104659-26-091671 |
| Document: 0001104659-26-091671-index.html | 0001104659-26-091671 |
| Document: 0001104659-26-091671.txt | 0001104659-26-091671 |
| 8-K Data (Synthetic) | 0001104659-26-091671 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 6, 2026 8w ago | 8-K | $44.42 $41.95 | ▼ −5.56% | ▼ −6.16% | $41.22 (−7.20%) |
Jul 13, 2026 11w ago | 8-K | $41.27 $44.58 | ▲ +8.02% | ▲ +4.84% | $41.22 (−0.12%) |
Jun 1, 2026 17w ago | 8-K | $40.26 $40.63 | ▲ +0.92% | ▲ +2.22% | $41.22 (+2.38%) |
May 7, 2026 21w ago | 8-K | $35.58 $36.21 | ▲ +1.77% | ▼ −1.37% | $41.22 (+15.85%) |
Apr 23, 2026 23w ago | DEFA14A | $31.58 $32.69 | ▲ +3.51% | ▼ −0.51% | $41.22 (+30.53%) |
Mar 27, 2026 26w ago | 144 | $30.28 $30.99 | ▲ +2.34% | ▼ −10.25% | $41.22 (+36.13%) |
Feb 26, 2026 31w ago | 8-K | $29.66 $31.65 | ▲ +6.71% | ▲ +13.11% | $41.22 (+38.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access